Trial Profile
Dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to chemotherapy treated with pegfilgrastim
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Sponsors Amgen
- 25 May 2017 Recruitment is completed according to results published in the Wiener Klinische Wochenschrift
- 25 May 2017 New trial record